The National Alzheimer’s Coordinating Center unites the collections of the neuropathology cores at 27 NIA-funded AD Research Centers into a single database. It contains records on 13,000 brains, 3,000 ...

Good managers set the tone for the whole team, encouraging positive behavior from everyone around them. In the November 5 Nature, scientists introduce a subtype of microglia that appears to do just ...

PSEN1 encodes presenilin-1, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. More than 300 mutations in PSEN1 have been reported and mutations in PSEN1 are the most ...

This brain bank stores frozen tissue. All donations go in through the lab's clinical core, and have been tested and diagnosed. The lab shares brain tissue through its biospecimen core.

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...

The gene PSEN2 encodes presenilin-2, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. Missense mutations in PSEN2 are a rare cause of early onset Alzheimer's disease.

An interactive timeline of the evolution of Alzheimer's Disease research.

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...